The cost of schizophrenia in Japan

Mitsuhiro Sado,1 Ataru Inagaki,2 Akihiro Koreki,1 Martin Knapp,3 Lee Andrew Kissane,4 Masaru Mimura,1 Kimio Yoshimura4 1Department of Neuropsychiatry, Keio University School of Medicine, 2Center for Clinical Psychopharmacology, Institute of Neuropsychiatry, Tokyo, Japan; 3Department of Social Policy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sado M, Inagaki A, Koreki A, Knapp M, Kissane LA, Mimura M, Yoshimura K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/d466e16dfe2a49bb9518578ce2268467
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d466e16dfe2a49bb9518578ce2268467
record_format	dspace
spelling	oai:doaj.org-article:d466e16dfe2a49bb9518578ce22684672021-12-02T07:34:35ZThe cost of schizophrenia in Japan1176-63281178-2021https://doaj.org/article/d466e16dfe2a49bb9518578ce22684672013-05-01T00:00:00Zhttp://www.dovepress.com/the-cost-of-schizophrenia-in-japan-a13199https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Mitsuhiro Sado,1 Ataru Inagaki,2 Akihiro Koreki,1 Martin Knapp,3 Lee Andrew Kissane,4 Masaru Mimura,1 Kimio Yoshimura4 1Department of Neuropsychiatry, Keio University School of Medicine, 2Center for Clinical Psychopharmacology, Institute of Neuropsychiatry, Tokyo, Japan; 3Department of Social Policy, London School of Economics and Political Science, London, UK; 4Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan Introduction: Schizophrenia is a disorder that produces considerable burdens due to its often relapsing/remitting or chronic longitudinal course. This burden is felt not only by patients themselves, but also by their families and health care systems. Although the societal burden caused by this disorder has been evaluated in several countries, the magnitude of the societal cost of schizophrenia in Japan has never been estimated. The aim of this study is to clarify the societal burden of schizophrenia by estimating the cost of schizophrenia in Japan in 2008. Methods: A human capital approach was adopted to estimate the cost of schizophrenia. The total cost of schizophrenia was calculated as the sum of the direct, morbidity, and mortality costs. Schizophrenia was defined as disorders coded as F20.0–F20.9 according to the International Classification of Diseases-10. The data required to estimate the total cost was collected from publicly available statistics or previously reported studies. Results: The total cost of schizophrenia in Japan in 2008 was JPY 2.77 trillion (USD 23.8 billion). While the direct cost was JPY 0.770 trillion (USD 6.59 billion), the morbidity and mortality costs were JPY 1.85 trillion (USD 15.8 billion) and JPY 0.155 trillion (USD 1.33 billion), respectively. Conclusion: The societal burden caused by schizophrenia is tremendous in Japan, similar to that in other developed countries where published data exist. Compared with other disorders, such as depression or anxiety disorders, the direct cost accounted for a relatively high proportion of the total cost. Furthermore, absolute costs arising from unemployment were larger, while the prevalence rate was smaller, than the corresponding results for depression or anxiety in Japan. Keywords: cost of illness, schizophrenia, societal burden, cost analysis, societal costSado MInagaki AKoreki AKnapp MKissane LAMimura MYoshimura KDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 787-798 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Sado M Inagaki A Koreki A Knapp M Kissane LA Mimura M Yoshimura K The cost of schizophrenia in Japan
description	Mitsuhiro Sado,1 Ataru Inagaki,2 Akihiro Koreki,1 Martin Knapp,3 Lee Andrew Kissane,4 Masaru Mimura,1 Kimio Yoshimura4 1Department of Neuropsychiatry, Keio University School of Medicine, 2Center for Clinical Psychopharmacology, Institute of Neuropsychiatry, Tokyo, Japan; 3Department of Social Policy, London School of Economics and Political Science, London, UK; 4Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan Introduction: Schizophrenia is a disorder that produces considerable burdens due to its often relapsing/remitting or chronic longitudinal course. This burden is felt not only by patients themselves, but also by their families and health care systems. Although the societal burden caused by this disorder has been evaluated in several countries, the magnitude of the societal cost of schizophrenia in Japan has never been estimated. The aim of this study is to clarify the societal burden of schizophrenia by estimating the cost of schizophrenia in Japan in 2008. Methods: A human capital approach was adopted to estimate the cost of schizophrenia. The total cost of schizophrenia was calculated as the sum of the direct, morbidity, and mortality costs. Schizophrenia was defined as disorders coded as F20.0–F20.9 according to the International Classification of Diseases-10. The data required to estimate the total cost was collected from publicly available statistics or previously reported studies. Results: The total cost of schizophrenia in Japan in 2008 was JPY 2.77 trillion (USD 23.8 billion). While the direct cost was JPY 0.770 trillion (USD 6.59 billion), the morbidity and mortality costs were JPY 1.85 trillion (USD 15.8 billion) and JPY 0.155 trillion (USD 1.33 billion), respectively. Conclusion: The societal burden caused by schizophrenia is tremendous in Japan, similar to that in other developed countries where published data exist. Compared with other disorders, such as depression or anxiety disorders, the direct cost accounted for a relatively high proportion of the total cost. Furthermore, absolute costs arising from unemployment were larger, while the prevalence rate was smaller, than the corresponding results for depression or anxiety in Japan. Keywords: cost of illness, schizophrenia, societal burden, cost analysis, societal cost
format	article
author	Sado M Inagaki A Koreki A Knapp M Kissane LA Mimura M Yoshimura K
author_facet	Sado M Inagaki A Koreki A Knapp M Kissane LA Mimura M Yoshimura K
author_sort	Sado M
title	The cost of schizophrenia in Japan
title_short	The cost of schizophrenia in Japan
title_full	The cost of schizophrenia in Japan
title_fullStr	The cost of schizophrenia in Japan
title_full_unstemmed	The cost of schizophrenia in Japan
title_sort	cost of schizophrenia in japan
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/d466e16dfe2a49bb9518578ce2268467
work_keys_str_mv	AT sadom thecostofschizophreniainjapan AT inagakia thecostofschizophreniainjapan AT korekia thecostofschizophreniainjapan AT knappm thecostofschizophreniainjapan AT kissanela thecostofschizophreniainjapan AT mimuram thecostofschizophreniainjapan AT yoshimurak thecostofschizophreniainjapan AT sadom costofschizophreniainjapan AT inagakia costofschizophreniainjapan AT korekia costofschizophreniainjapan AT knappm costofschizophreniainjapan AT kissanela costofschizophreniainjapan AT mimuram costofschizophreniainjapan AT yoshimurak costofschizophreniainjapan
_version_	1718399368185249792

The cost of schizophrenia in Japan

Ejemplares similares